Using FKBP51 blockers to stop chronic pain after trauma
FKBP51 antagonism to prevent chronic pain: optimizing efficacy & evaluating safety and mechanisms
This study is looking at how stopping a certain protein called FKBP51 might help people who have gone through trauma avoid long-lasting pain, especially those who are at risk after experiencing acute pain and are visiting the emergency room.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10795700 on NIH RePORTER |
What this research studies
This research investigates how blocking a specific protein, FKBP51, can help prevent chronic pain in individuals who have experienced traumatic stress. The study focuses on patients who are at high risk for developing chronic pain after acute pain episodes, particularly those seeking emergency care. By understanding the mechanisms of FKBP51 and its role in the stress response, the researchers aim to develop a new therapeutic approach that could effectively reduce the incidence of chronic pain and opioid misuse. The methodology includes evaluating the timing, dosage, and duration of FKBP51 inhibition to optimize its effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 who have recently experienced traumatic stress and are at high risk for developing chronic pain.
Not a fit: Patients who have not experienced traumatic stress or those with pre-existing chronic pain conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the number of patients who develop chronic pain after trauma, thereby decreasing reliance on opioids.
How similar studies have performed: Previous research has shown promise in targeting FKBP51 for pain management, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Linnstaedt, Sarah — Univ of North Carolina Chapel Hill
- Study coordinator: Linnstaedt, Sarah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.